← Back
$NRIX All transactions

Nurix Therapeutics, Inc.

M

$ Value

$0

Shares

3,750

Price

$0

Filed

Jan 30

Insider

Name

Hansen Gwenn

Title

Chief Scientific Officer

CIK

0001817160

Roles

Officer

Transaction Details

Transaction Date

2026-01-30

Code

M

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

85,708

Footnotes

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. | Represents the weighted average sale price. The lowest price at which shares were sold was $16.33 and the highest price at which shares were sold was $17.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. | Represents the weighted average sale price. The lowest price at which shares were sold was $17.33 and the highest price at which shares were sold was $17.49. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. | Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. | The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. | RSUs do not expire; they either vest or are canceled prior to the vest date. | The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. | The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. | The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Filing Info

Accession No.

0001817160-26-000002

Form Type

4

Issuer CIK

0001549595

Hansen Gwenn's History

Date Ticker Type Value
2026-02-10 NRIX A $0
2026-02-10 NRIX A $0
2026-02-03 NRIX M $26K
2026-02-03 NRIX M $0
2026-01-30 NRIX M $0
2026-01-30 NRIX M $0
2026-01-30 NRIX M $0
2026-01-30 NRIX M $0
2026-01-30 NRIX $80K
2026-01-30 NRIX $2K

Other Insiders at NRIX (90d)

Insider Bought Sold Last
SANDS ARTHUR T
President, CEO
2026-02-10
Hansen Gwenn
Chief Scientific Officer
$81K 2026-02-10
Ring Christine
Chief Legal Officer
$561K 2026-04-02
van Houte Hans
Chief Financial Officer
$61K 2026-02-10